Immunologic predictors of IL-2 response: Treg:Tcon ratios
| Week . | Trials . | Treg:Tcon . | Nonresponse, % . | Response (PR), % . | P . |
|---|---|---|---|---|---|
| 0 | Phase 2 | ≥0.07 | 20 | 64.7 | .046 |
| Phase 1 and 2 combined | ≥0.07 | 25 | 71.4 | .003 | |
| 1 | Phase 2 | ≥0.2 | 27.3 | 100 | .00015 |
| Phase 1 and 2 combined | ≥0.2 | 26.3 | 85 | .0003 |
| Week . | Trials . | Treg:Tcon . | Nonresponse, % . | Response (PR), % . | P . |
|---|---|---|---|---|---|
| 0 | Phase 2 | ≥0.07 | 20 | 64.7 | .046 |
| Phase 1 and 2 combined | ≥0.07 | 25 | 71.4 | .003 | |
| 1 | Phase 2 | ≥0.2 | 27.3 | 100 | .00015 |
| Phase 1 and 2 combined | ≥0.2 | 26.3 | 85 | .0003 |
Treg:Tcon ratios at baseline (week 0) and 1 week after start of IL-2 therapy (week 1). Data for phase 2, and combined phase 1 and 2 trials are presented separately.